Cite
HARVARD Citation
Kallieri, M. et al. (2022). RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response. Allergy. 77 (9), pp. 2848-2852. [Online].